ACR Meeting Abstracts

ACR Meeting Abstracts

Session » Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety and Efficacy of Small Molecule Agents

Meeting: 2013 ACR/ARHP Annual Meeting

Abstract Number: 1792
Inhibition Of Chemokine Receptors CCR1 and CCR6 As Promising Therapies For Autoimmune Diseases Such As Rheumatoid Arthritis and Psoriasis
Abstract Number: 1793
Oskira-1: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Methotrexate
Abstract Number: 1794
The Jak Inihibitor Tofacitinib Suppresses Synovial Jak-Stat Signalling In Rheumatoid Arthritis
Abstract Number: 1795
An Active Metabolite Contributes To The Pharmacodynamics and Efficacy Of GLPG0634, a Selective JAK1 Inhibitor
Abstract Number: 1796
12-Week Results Of a Phase 2b Dose-Ranging Study Of Baricitinib, An Oral JAK1/ JAK2 Inhibitor In Japanese Patients With Rheumatoid Arthritis On Background Methotrexate Therapy
Abstract Number: 1797
A Randomized, Dose-Ranging, Placebo-Controlled, 84-Day Study Of INCB039110, a Selective Janus Kinase-1 Inhibitor, In Patients With Active Rheumatoid Arthritis

« View all sessions from this meeting